Product information leaflets

Product information on COVID-19 vaccines and medicines is available on this page.

This information is a copy of the product information for COVID-19 vaccines and medicines, which outlines the conditions under which the products should be used and information on its known safety.
This information may be updated, if necessary.
The MHRA is unable to offer medical advice and so if a patient has any questions about a vaccine they should contact their doctor or pharmacist. Suspected adverse reactions to a COVID-19 vaccine or medicine can be reported to us on a Yellow Card.

The Information for healthcare professionals document is a description of a medicinal product’s properties and the conditions attached to its use. It explains how to use and prescribe a medicine or vaccine. It is used by healthcare professionals, such as doctors, nurses and pharmacists.

The Information for UK recipients document provides information for patients. This is based on the Information for healthcare professionals of the product.

Vaccines

Information about the Pfizer/BioNTech COVID-19 vaccine, approved for supply by MHRA on 2 December 2020

Find out more about the approval from our press release.

Further details about the regulatory approval of Pfizer / BioNTech vaccine for COVID-19

Information about the AstraZeneca vaccine, approved for supply by MHRA on 30 December 2020

Find out more about the approval from our press release.

Further details about the regulatory approval of COVID-19 Vaccine AstraZeneca

Information about the Moderna vaccine, approved for supply by MHRA on 8th January 2021

Find out more about the approval from our press release.

Further details about the regulatory approval of COVID-19 Vaccine Moderna

Information about the Paediatric Pfizer/BioNtech vaccine for children 5 to 11 years, approved for supply by MHRA on 22nd December 2021

Find out more about the approval from our press release.

Further details about the regulatory approval of Paediatric COVID-19 Vaccine Pfizer/BioNTech

Therapeutics

Information about Molnupiravir, approved for supply by MHRA on 4th November 2021

Find out more about the approval from our press release.

Further details about the regulatory approval of Molnupiravir